Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise
Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise
Combination therapy with idelalisib better prevents disease progression in relapsed or treatment-resistant chronic lymphocytic leukaemia than current regimen
Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia
First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia significantly improves survival
Exciting evidence for first all-oral treatment for relapsed and treatment-resistant multiple myeloma
Study finds new use for rituximab in acute lymphoblastic leukaemia
First targeted therapy for multiple myeloma effective against hard-to-treat disease
First targeted therapy for genetically defined subset with acute myeloid leukaemia significantly improves survival
Variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified
Immunotherapy makes patients’ tumours "melt away"
Quality assessment looking at rivaroxaban for cancer-related thrombosis
Guidance for anticoagulation management in the setting of thrombocytopenia in cancer patients